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Background: High-sensitivity cardiac troponin assays enable myocardial infarction to be ruled 
out earlier, but the safety and efficacy of this approach is uncertain. We investigated whether an 
early-rule out pathway is safe and effective for patients with suspected acute coronary syndrome. 
Methods: We performed a stepped-wedge cluster randomized controlled trial in the Emergency 
Departments of seven acute care hospitals in Scotland. Consecutive patients presenting with 
suspected acute coronary syndrome between December 2014 and December 2016 were included. 
Sites were randomized to implement an early rule-out pathway where myocardial infarction was 
excluded if high-sensitivity cardiac troponin I concentrations were <5 ng/L at presentation. 
During a prior validation phase, myocardial infarction was ruled out where troponin 
concentrations were <99th centile at 6–12 hours after symptom onset. The co-primary outcome 
was length of stay (efficacy), and myocardial infarction or cardiac death after discharge at 30 
days (safety). Patients were followed for 1 year to evaluate safety and other secondary outcomes.  
Results: We enrolled 31,492 patients (59±17 years, 45% women) with troponin concentrations 
<99th centile at presentation. Length of stay was reduced from 10.1±4.1 to 6.8±3.9 hours 
(adjusted geometric mean ratio 0.78, 95% confidence interval [CI] 0.73 to 0.83, P<0.001) 
following implementation, and the proportion of patients discharged increased from 50% to 71% 
(adjusted odds ratio [aOR] 1.59, 95% CI 1.45 to 1.75). Non-inferiority was not demonstrated for 
the 30-day safety outcome (upper limit of one-sided 95% CI for adjusted risk difference 0.70%, 
non-inferiority margin 0.50%, P=0.068), but the observed differences favoured the early rule-out 
pathway (0.4% [57/14,700] versus 0.3% [56/16,792]). At 1 year, the safety outcome occurred in 
2.7% (396/14,700) and 1.8% (307/16,792) of patients before and after implementation (aOR 
1.02, 95% CI 0.74 to 1.40, P=0.894), and there were no differences in hospital reattendance or 
all-cause mortality.  
Conclusions: Implementation of an early rule-out pathway for myocardial infarction reduced 
length of stay and hospital admission. Whilst non-inferiority for the safety outcome was not 
demonstrated at 30 days, there was no increase in cardiac events at 1 year. Adoption of this 
pathway would have major benefits for patients and healthcare providers. 
Clinical Trial Registration: URL: https://www.clinicaltrials.gov Unique Identifier: 
NCT03005158 
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Non-standard Abbreviations and Acronyms 
HiSTORIC   High-Sensitivity cardiac Troponin On presentation to Rule out myocardial 
InfarCtion trial  
High-STEACS High-Sensitivity Troponin in the Evaluation of patients with suspected 
Acute Coronary Syndrome early rule-out pathway 
LoDED Limit of Detection and ECG Discharge trial  
NHS   National Health Service 
RAPID-TnT Rapid assessment of possible acute coronary syndrome in the emergency 












What is new? 
 
• Patients with suspected acute coronary syndrome frequently attend Emergency 
Departments, but the majority do not have myocardial infarction. 
• Across 31,492 consecutive patients presenting to seven hospitals, implementation of an 
early rule-out pathway for patients with suspected acute coronary syndrome reduced 
length of stay by 3.3 hours and hospital admissions by 59%. 
• Non-inferiority was not demonstrated, but observed differences in myocardial infarction 
or cardiac death at 30 days and 1 year favoured the early rule-out pathway over standard 
care. 
 
What are the clinical implications? 
• Existing early rule-out pathways for myocardial infarction are largely based on 
observational studies or small trials of selected patients. 
• This trial provides evidence in consecutive patients with suspected acute coronary 
syndrome that the use of an early rule-out pathway is both safe and effective. 
• Adoption of an early-rule out pathway for myocardial infarction would have major 












There are over 20 million presentations with suspected acute coronary syndrome each year in the 
US alone,1 accounting for up to a tenth of hospital visits and 40 percent of unscheduled 
admissions.2 Given that most patients do not have myocardial infarction,3 the adoption of 
effective and safe pathways to rule out myocardial infarction in the Emergency Department and 
avoid hospital admission would have a major impact on patient care and healthcare provision.  
 Cardiac troponin testing is an integral component of the assessment of patients with 
suspected acute coronary syndrome, with guidelines recommending serial testing to rule in and 
rule out myocardial infarction.4 The development of high-sensitivity cardiac troponin assays with 
enhanced precision at very low concentrations permits quantification well below the 99th centile 
diagnostic threshold for myocardial infarction.5 This advance has led to innovative pathways to 
rule out myocardial infarction more rapidly, either at presentation or within 3 hours that have 
been incorporated into clinical practice guidelines.6-14 However, these studies were 
observational, and there are few examples where the pathway guided patient care.15,16 The 
majority were modest in size, or enrolled selected low-risk patients, and therefore the true 
efficacy and safety of introducing these pathways into clinical practice remains uncertain.  
Our aim was to determine the efficacy and safety of implementing an accelerated 
pathway where high-sensitivity cardiac troponin testing is used to rule out myocardial infarction 














Trial Design and Oversight 
High-Sensitivity cardiac Troponin On presentation to Rule out myocardial InfarCtion 
(HiSTORIC) is a stepped-wedge cluster randomized controlled trial enrolling consecutive 
patients with suspected acute coronary syndrome across seven acute hospitals in Scotland. In this 
trial, the hospital site was the unit of randomization and therefore individual patient consent was 
not sought. Cluster randomization was necessary to avoid the risk of clinical error due to 
simultaneous use of different diagnostic pathways. The trial was approved by the Scotland A 
Research Ethics Committee and the conduct of the trial was periodically reviewed by an 
independent trial steering committee. All data were collected from the patient record and national 
registries, deidentified and linked in a data repository (DataLoch, Edinburgh, UK) within secure 
NHS safe havens.17  
Trial Population  
Sites were eligible if they had the capacity to introduce the early rule-out pathway and returned 
data to the national registry. All patients were identified by the attending clinician using an 
electronic form integrated into the care pathway at the time troponin was requested. Patients 
were eligible for inclusion if they presented to the Emergency Department or Acute Medical 
Receiving Unit with suspected acute coronary syndrome and had a high-sensitivity cardiac 
troponin I concentration within the normal reference range (less than the sex-specific 99th centile 
upper reference limit) at presentation. Patients were excluded if they presented with an out-of-
hospital cardiac arrest or ST-segment elevation myocardial infarction, had been admitted 











The trial was conducted across three phases (Figure 1a). During all phases of the trial a high-
sensitivity cardiac troponin I assay with sex-specific 99th centile thresholds was used to guide 
care and rule-in myocardial infarction according to the Universal Definition of Myocardial 
Infarction.4 During a validation phase of 6-9 months, troponin testing was performed at 
presentation and repeated 6-12 hours after the onset of symptoms if indicated (standard care). In 
accordance with guidelines at the time of enrolment,4,18 myocardial infarction was ruled out 
where high-sensitivity cardiac troponin concentrations were less than the 99th centile at 
presentation if symptom onset was >6 hours from presentation, or following serial testing 6-12 
hours from symptom onset in those presenting earlier. Sites were paired based on the expected 
number of patients and randomized to implement the early rule-out pathway (intervention) in one 
of three steps during a 6-month randomization phase. Finally, all sites completed an 
implementation phase of 6-9 months calendar matched to the validation phase where care was 
guided by the early rule-out pathway.  
Intervention 
The High-Sensitivity Troponin in the Evaluation of patients with suspected Acute Coronary 
Syndrome (High-STEACS) early rule-out pathway (Figure 1b) has been described 
previously.19,20 Myocardial infarction is ruled out in patients with troponin concentrations <5 
ng/L at presentation, unless they present within 2 hours of symptom onset where testing is 
repeated 3 hours from presentation. Patients with troponin concentrations ≥5 ng/L at presentation 
are retested 3 hours after presentation, and myocardial infarction is ruled out if concentrations 
are unchanged (delta <3 ng/L) and remain below the 99th centile. To support implementation, we 









and formal training for clinical staff in the Emergency Department (Supplemental Material). 
Throughout the trial, all sites used the Abbott ARCHITECTSTAT high-sensitive troponin I assay 
to guide clinical decisions. This assay has an inter-assay coefficient of variation of less than 10% 
at 4.7 ng/L,8,21 and a 99th centile of 16 ng/L in women and 34 ng/L in men.22  
Trial Outcomes  
We used regional and national registries to follow-up the trial population.17,23-24 Sequential 
hypothesis testing evaluated two co-primary outcomes in an a-priori defined hierarchical order: 
the primary efficacy outcome followed by the primary safety outcome. The primary efficacy 
outcome was length of stay, defined as the length of time from presentation to the Emergency 
Department until discharge from hospital. The safety outcome was myocardial infarction (type 1, 
type 4b or type 4c) or cardiac death after discharge which was evaluated at 30 days (primary) 
and 1 year (secondary) following presentation. These events were adjudicated by a panel blind to 
the study phase. All subsequent presentations where any troponin concentration was >99th centile 
were reviewed and adjudicated as described previously (Supplemental Material).17,25-26   
The secondary efficacy outcome measure was the proportion of patients discharged from 
the Emergency Department. Other safety outcome measures included myocardial infarction, 
cardiac death, cardiovascular death, all-cause death, unplanned coronary revascularisation and 
reattendances for any reason after discharge at 1 year. Adherence was evaluated for three 
prespecified components of the early rule-out pathway (Supplemental Material). 
Statistical Analysis 
The primary efficacy outcome was analysed using a linear mixed-effects regression model, 
adjusting for hospital site (random effect), season, time of presentation since start of study, and 









safety outcome was analysed using a logistic mixed-effects regression model adjusting for the 
same covariates. For the primary efficacy analysis, length of stay was log-transformed prior to 
analysis and results expressed as a geometric mean ratio. If the analysis of the primary efficacy 
outcome was significant at the 5% level, then we planned to perform a non-inferiority analysis of 
the primary safety outcome reporting a risk difference (intervention–standard care) and one-
sided 95% confidence interval. If the upper limit of the one-sided 95% confidence interval was 
below a 0.5% non-inferiority margin, then non-inferiority was established, and if it was below 
0% then superiority was established. A sensitivity analysis compared outcomes during the 
calendar matched period in the validation and implementation phases using the same regression 
model as for the primary analysis, but without adjustment for time or season. A number of other 
sensitivity analyses were performed (Supplemental Material).  
Patient and public involvement 
A patient review panel was consulted throughout the trial programme and provided input on the 
educational advice provided to clinicians following introduction of the new pathway. Qualitative 
research capturing the views and experiences of patients treated within these pathways will 
follow in a separate publication. Patients were not involved in the conception or design of the 
trial. 
Data Sharing 
The HiSTORIC trial makes use of multiple routine electronic health care data sources that are 
linked, deidentified and held in the NHS national safe haven, which is accessible by approved 
individuals who have undertaken the necessary governance training. Summary data can be made 











Trial Sites and Population 
Seven acute hospitals were eligible and all participated (Table I in the Supplement). Between 
December, 2014, and December, 2016, a total of 31,492 consecutive patients with suspected 
acute coronary syndrome (59±17 years, 45% women) met the inclusion criteria (Figure 2). 
There were 14,700 (47%) and 16,792 (53%) patients assessed before and after implementation of 
the early rule-out pathway, respectively. Clinical characteristics were similar before and after 
implementation (Table 1) and across all three phases of the trial (Table II in the Supplement). 
The trial concluded in December, 2017 with 1 year of follow up available in 31,428 (99.8%) 
patients.  
Primary and Secondary Efficacy Outcomes 
Length of stay was reduced from 10.1±4.1 to 6.8±3.9 hours (adjusted geometric mean ratio 0.78, 
95% confidence interval [CI] 0.73 to 0.83, P<0.001) following implementation of the early rule-
out pathway (Table 2, Figure 3). The proportion of patients discharged from the Emergency 
Department without hospital admission increased from 50% to 71% (adjusted odds ratio 1.59, 
95% CI 1.45 to 1.75). Adherence to all three prespecified components of the early rule-out 
pathway was observed in 11,600/16,792 (69%) of patients.  
Primary and Secondary Safety Outcomes 
Before and after implementation of the early rule-out pathway, the primary safety outcome of 
myocardial infarction or cardiac death following discharge at 30 days occurred in 57/14,700 
(0.4%) and 56/16,792 (0.3%) patients respectively (Table 2) with an adjusted odds ratio of 1.97 
(95% CI 0.95 to 4.08, P=0.068). Comparing the rate of the primary safety outcome after 









the adjusted risk difference was 0.70%, exceeding our prespecified non-inferiority margin of 
0.50%. The event rate at 30 days was lower than anticipated, and our regression model and 
prespecified sensitivity analyses gave divergent results (Table III in the Supplement). However, 
there were 703 (2.2%) patients with myocardial infarction or cardiac death following discharge 
at 1 year (Figure 4). Before and after implementation, the secondary safety outcome measure 
occurred in 396/14,700 (2.7%) and 307/16,792 (1.8%) patients, respectively (adjusted odds ratio 
1.02, 95% CI 0.74 to 1.40, P=0.894). This comprised 238 (1.6%) patients with myocardial 
infarction and 176 cardiac deaths (1.2%) during standard care, with 184 (1.1%) patients with 
myocardial infarction and 143 (0.9%) cardiac deaths after implementation of the early rule-out 
pathway. Furthermore, the rate of all other safety outcome measures at 1 year did not differ 
before and after implementation (Table 2). The findings were consistent in a post hoc analysis of 
the safety outcome which included type 2 myocardial infarction events (Table IV and Figure I 
in the Supplement). 
Sensitivity Analysis in Calendar Matched Validation and Implementation Phases 
In total 18,241 (58%) patients attended during the calendar-matched phases with 8,673 (48%) 
and 9,568 (52%) evaluated during the validation and implementation phase respectively (Table 
III in the Supplement). Length of stay was reduced from 10.6±4.1 to 6.8±4.0 hours (adjusted 
geometric mean ratio 0.65, 95% CI 0.62 to 0.68) before and after implementation of the early 
rule-out pathway. The primary safety outcome occurred in 43/8,673 (0.5%) and 23/9,568 (0.2%) 
patients at 30 days, with an adjusted odds ratio of 0.48 (95% CI 0.29 to 0.80, P=0.005). The 
upper limit of our one-sided 95% confidence interval for the adjusted risk difference was -0.13%, 









251/8,673 (2.9%) and 161/9,568 (1.7%) patients at 1 year (adjusted odds ratio 0.58, 95% CI 0.47 
to 0.71, P<0.001).  
 
Discussion 
We evaluated the efficacy and safety of implementing an early rule-out pathway in 31,492 
consecutive patients presenting with suspected acute coronary syndrome to the Emergency 
Department or Acute Medical Receiving Unit. Introducing the pathway into clinical practice 
reduced length of stay by 3.3 hours and increased the odds of patients avoiding hospital 
admission by 59%. Non-inferiority was not formally demonstrated, but the observed differences 
in myocardial infarction or cardiac death following discharge favoured the early rule-out 
pathway.  
There are several strengths of our pragmatic trial design. First, we embedded our 
screening tool into the patient record to ensure we prospectively enrolled consecutive patients 
whom the attending clinician suspected acute coronary syndrome. This minimized the risk of 
selection bias, ensuring we did not limit our findings to low-risk patients or those presenting 
within working hours. Second, as the intervention was implemented at the hospital level, we did 
not seek individual patient consent. This reduced the risk of a Hawthorne effect where 
effectiveness is exaggerated through direct observation of clinical care by researchers. Third, our 
trial population was larger than the combined number of patients enrolled in 30 previous 
observational studies.27,28 This ensured we had a greater number of events to evaluate safety. 
Finally, we combined hospital-level data with established registries to ensure follow up was 










The High-STEACS early rule-out pathway determines whether a patient with suspected 
acute coronary syndrome requires hospital admission or can be safely discharged. It is based on 
three principles. First, patients with very low troponin concentrations are at low-risk of cardiac 
events.6 We defined the optimal risk stratification threshold as the highest concentration that 
gave a negative predictive value of >99.5% for myocardial infarction or cardiac death at 30 
days,8,27 to maximize the effectiveness of this approach whilst maintaining safety. Second, 
increasing concentrations above this risk stratification threshold on repeat testing may be 
important, even if they remain within the normal reference range, and these patients require 
admission to measure peak troponin concentration.19 We define this using a change in 
concentration of ≥3 ng/L, based on the lowest measurable change that exceeds biological and 
analytical variation.29 Third, to ensure our pathway is consistent with international guidelines,4 
we applied the sex-specific 99th centile as the threshold to identify patients who require hospital 
admission. Adherence was good across all seven acute hospitals which is testament to the 
simplicity of the pathway and should encourage adoption.  
 Whilst many pathways that incorporate separate risk stratification and diagnostic 
thresholds have been described,12,30-32 these suffer from the same limitation as the High-STEACS 
pathway; no patient was managed according to these pathways during their derivation or 
validation. Guideline recommendations have therefore been based largely on observational data, 
with little understanding of the impact of these pathways in clinical practice. Here we have 
evaluated the implementation of an early rule-out pathway in a prospective randomized 
controlled trial of consecutive patients. We report substantial reductions in length of stay and 
increases in the proportion of patients avoiding hospital admission. Were these gains to be 









substantial. In the US alone, more than 20 million patients with suspected acute coronary 
syndrome attend Emergency Departments each year.1 A reduction in the length of stay of 3 hours 
could save more than $3.6 billion per annum on bed occupancy alone.33  
Despite these important reductions in length of stay, during the implementation phase the 
median stay was 6.8 hours, which is longer than reported in other evaluations of the 
implementation of early rule-out pathways.15,16,34 This difference likely reflects our enrollment of 
all consecutive patients rather than selected patients who are less likely to have co-morbid 
conditions requiring hospital admission. We also acknowledge that reductions in length of stay 
may differ in other healthcare settings. Although the European Society of Cardiology (ESC) 
guidelines have recommended high-sensitivity cardiac troponin testing and a 0/3-hour pathway 
based on the 99th centile since 2011,35 we did not adopt this as our standard of care, but instead 
followed the recommendations of our national guidelines.18 During the design phase of the trial, 
we prospectively validated the ESC 0/3 hour high-sensitivity cardiac troponin pathway and 
demonstrated that the diagnostic performance of serial testing at presentation and 3 hours 
compared to serial testing at presentation and 6-12 hours after symptom onset was poor with a 
sensitivity and negative predictive value for myocardial infarction of 89.3% and 97.9%, 
respectively.19 Our findings were consistent with those from an independent validation in 
Australia and New Zealand,36 and as a consequence the 2020 ESC guidelines no longer prefer 
this approach.37 It is essential that more prospective trials are conducted in which clinical 
decisions are guided by new diagnostic approaches if we are to ensure our clinical practice 
guidelines are based on the highest quality evidence.  
Implementation of our early rule-out pathway did not increase the rate of subsequent 









specification. Although non-inferiority was not concluded for the primary safety outcome at 30 
days, in our prespecified sensitivity analysis restricted to calendar matched periods, the early 
rule-out pathway was superior to standard care at 30 days and 1 year. These divergent results 
may be due to the low event rate at 30 days and narrow randomization phase leading to 
overfitting of the primary analysis model, additional secular changes not accounted for in the 
sensitivity analysis, or a true exposure-time effect whereby outcomes improved as the 
intervention became more firmly embedded into practice. We acknowledge that although the 
number of patients enrolled in each cluster (hospital) was large, the number of clusters was 
small, which may have made the trial more vulnerable to the effect of confounding bias 
occurring within individual sites. However, our analyses suggested that including site as a 
random effect in the model had negligible influence on the overall result. The low event rate for 
the safety outcome at 30 days and narrow randomization phase made it more likely for chance 
imbalances to occur between those managed according to the standard care and early rule-out 
pathway (Figure II in the Supplement). This may have produced partial confounding of our 
estimate of the effect of the intervention as the primary analysis model incorporates both vertical 
comparisons across sites as well as before-and-after comparisons within sites. Importantly, we 
also prespecified a calendar matched before-and-after sensitivity analysis that did not include a 
vertical comparison; the results of which favored the early-rule out pathway.  
Is it plausible that the introduction of an early rule-out pathway could reduce the risk of 
subsequent cardiac events? By using a threshold well below the 99th centile to risk stratify 
patients and by recognizing that small changes in troponin concentration within the reference 
range may be important, we may have improved the evaluation of risk compared to using a 









observational studies, which report that using the 99th centile to rule out myocardial infarction at 
presentation and at 3 hours, misses 1 in 10 patients with myocardial infarction who would have 
been identified on serial testing 6-12 hours following the onset of symptoms.19,36,38 Furthermore, 
our pathway encourages serial testing to safely rule out myocardial infarction in early presenters, 
which is now recognized by international guidelines.37,39  
Our findings add to those from two recently published randomized trials. The RAPID-
TnT study compared a 1-hour and 3-hour rule-out pathway in 3,378 patients, finding a 1-hour 
strategy reduced length of stay by 60 minutes and increased discharge rates from 32% to 45%.16 
The trial concluded non-inferiority for an endpoint of all-cause mortality or myocardial 
infarction within 30 days, although there was an increase in secondary safety outcome events in 
the 1-hour pathway arm. Due to a perceived lack of equipoise the monitoring committee 
recommended the trial stop recruitment with just two-thirds of the target population enrolled, and 
only one patient had a type 1 myocardial infarction following discharge in each arm. The Limit 
of Detection and ECG Discharge (LoDED) trial compared standard guideline care with a rule-
out pathway using the limit of detection of cardiac troponin in 632 patients.40 The use of a single 
test approach did not increase the proportion of patients discharged from hospital within four 
hours of presentation. This surprising finding may have been due to the small sample size and 
insufficient power or the enrollment of selected lower risk patients with a normal 
electrocardiogram. It appears that the treating clinician determined the probability of myocardial 
infarction to be sufficiently low that admission to hospital was not required in both arms of the 
trial. However, consistent with our observations, the LoDED investigators report that a single 










 We acknowledge several potential study limitations. First, whilst the early rule-out 
pathway was implemented across three steps in the randomization phase, we had to accept 
flexibility in the date of implementation (Supplemental Material). This limited our ability to 
interpret a planned sensitivity analysis within the randomization phase, when there were sites 
using both the standard care and early rule-out pathway. Second, we enrolled fewer than the 
38,994 patients anticipated in our sample size calculations, and identified fewer safety outcome 
events at 30 days. We believe this in part contributed to modelling issues when attempting to 
evaluate the safety outcome at 30 days. However, more than 700 patients had a myocardial 
infarction or cardiac death at 1 year, and the rates of all secondary outcome measures were lower 
following implementation of the early rule-out pathway. Third, the standard care arm of our trial 
used a serial testing strategy based on the time of onset of symptoms, rather than a fixed time 
point 3-6 hours from presentation which is more commonly used in other countries. Despite this 
limitation, 50% of patients were discharged directly from the Emergency Department in our 
standard care arm. Whilst there are differences in the inclusion criteria between trials, the 
proportion of patients discharged in our standard care arm was already higher than in either arm 
of the RAPID-TnT trial, which compared a 0/3 hour pathway (32% discharged) with a 0/1 hour 
pathway (45% discharged).16 Despite the high proportion of patients discharged in our standard 
care arm we increased the proportion discharged from 50% to 71% when implementing our early 
rule-out pathway. Fourth, we note that our early rule-out pathway does not recommend early 
serial testing in those with elevated cardiac troponin concentrations at presentation. In our 
previous trial,17 we observed that 2.7% of patients with suspected acute coronary syndrome have 
evidence of chronic myocardial injury.41 It is possible the effectiveness of our pathway could be 









patients with chronic myocardial injury are complex with significant cardiac and non-cardiac 
comorbidities and may benefit from further evaluation prior to discharge. Additional research to 
needed to evaluate the effectiveness of approaches to improve the rule-in of myocardial 
infarction.12,42 Finally, our pathway has been validated for use with two troponin I assays and a 
troponin T assay without modification,19,20,43.44 and whilst it is likely to perform similarly for 
other high-sensitivity assays, further research is required to confirm this.  
In conclusion, implementation of an early rule-out pathway for myocardial infarction 
substantially reduced length of stay and increased the proportion of patients avoiding hospital 
admission with no increase in adverse cardiac events. Adoption of this approach would have 
major benefits for both patients and healthcare providers. 
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Table 1. Characteristics of the Trial Participants 
 
Presented as No. (%), mean±SD or median [25th percentile, 75th percentile].]. Abbreviations: ACE = angiotensin 
converting enzyme; ARB = angiotensin receptor blockers; eGFR = estimated glomerular filtration rate; CABG = coronary 
artery bypass grafting; PCI = percutaneous coronary intervention. * Two medications from aspirin, clopidogrel, prasugrel 
or ticagrelor. † Includes warfarin or novel oral anti-coagulants. ‡ Proportions reported for the 16,217 (51%) participants 
with electrocardiographic data available. § Serial testing was defined as two or more tests within 24 hours of presentation. 
 All  Standard care  Early rule-out 
No. of participants 31,492 14,700 16,792 
Age (years) 59±17 59±17 58±17 
Women 14,252 (45) 6,575 (45) 7,677 (46) 
Presenting complaint    
  Chest pain 26,590 (84) 12,566 (85) 14,024 (84) 
  Dyspnoea 957 (3) 420 (3) 537 (3) 
  Palpitation 928 (3) 432 (3) 496 (3) 
  Syncope 1,701 (5) 699 (5) 1,002 (6) 
  Other 1,316 (4) 583 (4) 733 (4) 
Past medical history    
  Myocardial infarction 2,573 (8) 1,371 (9) 1,202 (7) 
  Ischaemic heart disease 7,346 (23) 3,834 (26) 3,512 (21) 
  Cerebrovascular disease 1,684 (5) 849 (6) 835 (5) 
  Diabetes mellitus 1,912 (6) 1,002 (7) 910 (5) 
Previous revascularization    
  PCI 2,831 (9) 1,534 (10) 1,297 (8) 
  CABG 452 (1) 240 (2) 212 (1) 
Medications at presentation    
  Aspirin 8,023 (25) 4,114 (28) 3,909 (23) 
  Dual anti-platelet therapy* 1,269 (4) 738 (5) 531 (3) 
  Statin 12,165 (39) 6,035 (41) 6,130 (37) 
  ACE inhibitor or ARB 9,769 (31) 4,776 (32) 4,993 (30) 
  Beta-blocker 8,548 (27) 4,162 (28) 4,386 (26) 
  Oral anti-coagulant † 2,167 (7) 1,033 (7) 1,134 (7) 
Electrocardiogram ‡    
  Normal  12,035 (74) 6,118 (73) 5,917 (75) 
  Myocardial ischemia 3,288 (20) 1,756 (21) 1,532 (20) 
  ST-segment elevation 193 (1) 111 (1) 82 (1) 
  ST-segment depression 252 (2) 146 (2) 106 (1) 
  T-wave inversion 1,225 (8) 621 (7) 604 (8) 
  Other 1,711 (11) 927 (11) 784 (10) 
Hematology and clinical chemistry    
  Hemoglobin, g/L  137±22 137±20 137±23 
  eGFR, mL/min 81±22 81±23 82±22 
  Presentation hs-cTnI, ng/L 3 [1-6] 3 [1-6] 3 [1-6] 
  Peak hs-cTnI, ng/L 3 [1-7] 3 [1-7] 3 [1-7] 
  Serial (≥2) tests § 11,904 (38) 6,540 (44) 5,364 (32) 
Time intervals    
  Symptom onset to presentation ≤2 hrs 5,664 (18) 2,859 (19) 2,805 (17) 
  Presentation to first test, mins 66 [45-97] 66 [46-97] 65 [43-97] 









Table 2. Efficacy and Safety Outcomes at 30 Days and 1 Year 
 
 All  
Standard 
care Early rule-out 
Adjusted Odds Ratio 
(95% CI)* P-value 
No. of participants n=31,492 n=14,700 n=16,792   
Efficacy outcome 
  Length of stay, hrs (primary) 8.2±4.1 10.1±4.1 6.8±4.1 0.78 (95% CI 0.73 to 0.83) P<0.001 
  Discharge from the ED (secondary) 19,249 (61) 7,407 (50) 11,842 (71) 1.59 (95% CI 1.45 to 1.75) P<0.001 
Safety outcome †  
  30 days (primary)  113 (0.4) 57 (0.4) 56 (0.3) 1.97 (95% CI 0.95 to 4.08) P=0.068  
  1 year (secondary) 703 (2.2) 396 (2.7) 307 (1.8) 1.02 (95% CI 0.74 to 1.40) P=0.894 
Other safety outcomes at 1 year  
  Myocardial infarction ‡ 422 (1.3) 238 (1.6) 184 (1.1) 1.10 (95% CI 0.72 to 1.68) P=0.646 
  Cardiac death 319 (1.0) 176 (1.2) 143 (0.9) 1.07 (95% CI 0.69 to 1.64) P=0.771 
  Cardiovascular death  452 (1.4) 249 (1.7) 203 (1.2) 0.93 (95% CI 0.66 to 1.32) P=0.696 
  All-cause death  1,720 (5.5) 852 (5.8) 868 (5.2) 0.92 (95% CI 0.75 to 1.12) P=0.385 
  Unplanned revascularisation § 222 (0.7) 119 (0.8) 103 (0.6) 0.60 (95% CI 0.35 to 1.03) P=0.065 
  Any hospital reattendance  12,306 (39.1) 5,770 (39.3) 6,536 (38.9) 0.93 (95% CI 0.84 to 1.02) P=0.112 
Presented as geometric mean ± standard deviation or No. (%). Abbreviations: CI = confidence interval, ED = Emergency 
Department  
* Outcomes following implementation of the early rule-out pathway are compared to those during standard care for all 
measures. For length of stay this is an adjusted ratio of the geometric mean rather than an odds ratio.  
† Type 1, type 4b or type 4c myocardial infarction or cardiac death following discharge.  
‡ Type 1, type 4b or type 4c myocardial infarction 
§ Unplanned revascularisation was defined as urgent or emergency percutaneous coronary intervention or coronary artery 
bypass grafting from discharge to 1 year  
 








Figure Legends  
 
Figure 1. Schematic diagram of the HiSTORIC trial design and the early-rule out pathway 
a) A high-sensitivity cardiac troponin I assay with sex-specific 99th centile thresholds was used 
to guide care and rule-in myocardial infarction during all phases of the trial. During a validation 
phase of at least 6 months, cardiac troponin testing was performed at presentation and was 
repeated 6 or 12 hours after the onset of symptoms if indicated. Myocardial infarction was ruled 
out where high-sensitivity cardiac troponin concentrations were less than the 99th centile at 
presentation if symptom onset was >6 hours from presentation, or following serial testing 6-12 
hours from symptom onset in those presenting earlier (standard care). Sites were paired based on 
the expected number of patients and randomized to implement the early rule-out pathway 
(intervention) in one of three steps during a 6 month randomization phase. Finally, all sites 
completed an implementation phase of at least 6 months that was calendar matched to the 
validation phase where patient care was guided by the early rule-out pathway. 
b) The early rule-out pathway rules out myocardial infarction at presentation in patients with 
cardiac troponin concentrations below a risk stratification threshold of 5 ng/L, unless they 
presented within 2 hours of symptom onset where testing is repeated 3 hours from presentation. 
Patients with cardiac troponin concentrations ≥5 ng/L at presentation are retested in the 
Emergency Department 3 hours after presentation, and myocardial infarction is ruled out if 












Figure 2. The HiSTORIC trial CONSORT diagram 
Figure 3. Length of stay before and after implementation of the early rule-out pathway 
Shown is a density plot of the length of stay in patients evaluated before (blue) and after (red) 
implementation of the early rule-out pathway.  
Figure 4. Myocardial infarction or cardiac death following discharge before and after 
implementation of the early rule-out pathway 
Shown are cumulative incidence time-to-event curves for the primary safety outcome of 
myocardial infarction or cardiac death for patients evaluated before (blue line) and after (red 
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